Engel Law PLLC is investigating whether fair value to Prometheus shareholders will result from the proposed acquisition of Prometheus Biosciences, Inc. (NASDAQ: RXDX) by Merck (NYSE: MRK) for $200 in cash for each Prometheus share.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.